Immunohistochemical analysis and correlation of cyclooxygenase-2 expression status with clinicopathological parameters in head and neck squamous cell carcinomas: An Indian perspective

Prerna Chadha, Richa Ranjan, Nikhilesh Kumar, Rig Vardhan, Prashant Sengupta, Rakhi Negi
Department of Laboratory Medicine, Command Hospital (Central Command), Lucknow, Uttar Pradesh, India

Abstract

Context: Head and neck squamous cell carcinoma (HNSCC) poses a major health problem and despite the advancements in its diagnosis and management the overall survival has not improved significantly. A search for newer diagnostic and prognostic markers along with fresh molecular targets is required for its prevention and cure.

Aims: The study aims to study the expression of cyclooxygenase-2 (COX-2) in HNSCCs and investigate its correlation with the clinicopathological profile of these cases. This study was performed to determine the significance of COX-2 expression in the Indian context.

Settings and Design: This study incorporated 90 cases of HNSCCs; both prospectively and retrospectively in a tertiary care center.

Materials and Methods: Expression of COX-2 on immunohistochemistry (IHC) was evaluated in correlation with the histological grade, maximum tumor size, tumor depth, nodal status and lymphovascular/perineural invasion (lvi/pni). The study received a waiver from the institutional ethics committee.

Statistical Analysis Used: Statistical analysis of the data was done using SPSS software.

Results: COX-2 expression was found in 97.8% of the cases. A statistically significant correlation of COX-2 immunopositivity was found with the histological grade, clinical staging (tumor size and nodal status), maximum tumor depth and lvi/pni in our study ($P < 0.05$).

Conclusions: COX-2 is expressed by most of the cases in this study. Its expression is related to tumor growth, differentiation and aggressiveness and therefore can be used as a good independent prognostic marker in HNSCCs. There is also possible scope of using it for targeted therapy in HNSCCs.

Keywords: Cyclooxygenase-2, head and neck squamous cell carcinoma, immunohistochemistry

Access this article online

Quick Response Code:  
Website: www.jomfp.in
DOI: 10.4103/jomfp.JOMFP_128_20

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Chadha P, Ranjan R, Kumar N, Vardhan R, Sengupta P, Negi R. Immunohistochemical analysis and correlation of cyclooxygenase-2 expression status with clinicopathological parameters in head and neck squamous cell carcinomas: An Indian perspective. J Oral Maxillofac Pathol 2020;24:583-4.
INTRODUCTION

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common neoplasm worldwide and poses a major health problem. India contributes its fair share to the worldwide disease burden and accounts for about 30% of all new cases annually.[3]

Despite the advancements in the diagnosis and management of patients with HNSCCs, the overall survival has not improved significantly.[2] Moreover, second primary cancers are very common in these patients.[1] In view of these observations, a search for newer diagnostic and prognostic markers along with fresh molecular targets is required for the prevention and cure of HNSCCs and related tumors.

Cyclooxygenases (COXs) are enzymes which catalyze the synthesis of prostaglandins (PGs) from arachidonic acid. PGs are well known to be associated with cell proliferation and angiogenesis, thus playing a pivotal role in carcinogenesis.[4,5] Overexpression of COX-2 has been documented in various cancers, such as those of the colon, stomach, lung, esophagus and oral cancers. However, there is ambiguity regarding the COX-2 expression in HNSCCs and its correlation with tumor size, grade, tumor depth, nodal status, distant metastasis and lymphovascular/perineural invasion (lvi/pni).[6-10]

This study aims to assess the immunohistochemical expression of COX-2 in HNSCCs and investigate its correlation and significance with the clinicopathological profile of these cases in an Indian context. The importance of studying COX-2 expression status lies in the fact that targeted therapy against this protein is available and has great potential.

MATERIALS AND METHODS

This study incorporated 90 cases of HNSCCs, both prospectively and retrospectively presenting to the oncology department of this institute between December 2012 and May 2015. The cases were retrieved from the departmental archives. Hematoxylin and eosin (H and E) staining and immunohistochemistry (IHC) was performed for COX-2 on relevant sections as per the standard protocol. Negative and positive control slides were included in each IHC run (as recommended by the manufacturers). Relevant clinical data in the form of case sheets, laboratory and radiological investigations were collected and noted.

Small biopsy specimens, cases with recurrent HNSCC postchemo/radiotherapy, cases other than squamous cell carcinoma and cancers of the thyroid and salivary glands were excluded from the study.

Immunohistochemistry staining procedure

IHC was performed on 4 µm formalin-fixed paraffin-embedded sections. The COX-2 (clone SP21) rabbit monoclonal antibody; ready to use kit (thermo scientific) was used on sections fixed on poly L lysine coated slides. Heat-induced antigen retrieval was performed for 1 h followed by endogenous peroxidase blocking. After which primary antibody (COX-2 clone SP21) and visualization reagent (labeled horse radish peroxidase secondary antibody) were added. In the end, substrate chromogen solution diaminobenzidine (DAB) was used. Sections were then counterstained and mounted.

ASSESSMENT OF IHC RESULTS

The assessment of IHC results was done on the basis of percentage of tumor cells showing membrane/cytoplasmic staining and intensity of staining as described in Table 1.

For the purpose of our study, cytoplasmic staining with a score 2+, 3+ and 4+ were taken as overexpression while 1+ was taken as underexpression. A score of 0 was taken as negative expression. This was done as per guidelines described by Abrahao et al.[11]

Statistical analysis

The statistical analysis was done using Company name SPSS Inc., Chicago, Illinois, U.S.A statistical analysis software. The values were represented in number (%) and mean ± standard deviation. Student’s t-test was used to test the significance of two means. Analysis of variance test was used to compare the within group and between group variances amongst the study groups. The level of significance “P” value was considered statistically significant if <0.05.

Ethical approval

The study received a waiver from the institutional ethics committee.

Table 1: Interpretation and scoring of cyclooxygenase-2 immunohistochemical staining

| Score | Surgical specimen - Staining pattern | COX2 expression assessment |
|-------|-------------------------------------|--------------------------|
| 0     | Weak staining in 0%- 10% of tumor cells | Negative |
| 1+    | Weak to moderate staining in 10%- 25% of tumor cells | Equivocal |
| 2+    | Moderate to strong staining in 25%- 50% of tumor cells | Positive |
| 3+    | Strong staining in 50%- 75% of tumor cells | Positive |
| 4+    | Strong staining in 75%- 100% of tumor cells | Positive |

COX-2: Cyclooxygenase-2
RESULTS

Clinicopathological data
The study sample comprised of 90 cases of HNSCCs which included 72 males (80%) and 18 females (20%). Most of the cases were well differentiated histopathologically ($n = 52; 57.8\%$) [Figure 1a] while 37 cases (41.1%) were moderately differentiated [Figure 1b]. Only one case (1.1%) was poorly differentiated [Figure 1c]. Maximum number of cases in this study presented with a clinical stage of T2 ($n = 45; 50.0\%$) and most of the patients did not show nodal involvement at presentation ($n = 67; 74.4\%$). In our study, the depth of tumor ranged from 0.1 cm to 3.5 cm. 48.9% of the patients ($n = 44$) had a tumor depth between 0.5 and 1 cm.

EVALUATION OF IHC RESULTS

COX-2 expression score was $1+$ in 19 (21.1%) [Figure 2b] of the cases, $2+$ in 57 (63.3%) [Figure 3a], $3+$ in 5 (5.6%) [Figure 3b] and $4+$ in 7 (7.8%) [Figure 3c] cases respectively. No expression was observed in 2 (2.2%) [Figure 2a] of the cases. For the purpose of our present study, score of $2+$, $3+$ and $4+$ were taken as indicators of overexpression. Hence, 76.7% ($n = 69$) of the cases showed COX-2 overexpression.

Association between cyclooxygenase-2 expression and clinicopathological parameters
COX-2 expression showed a significant association with the histopathological grade of the tumor, clinical staging, maximum tumor depth, nodal status and lvi/pni ($P < 0.05$). No significant association was found with distant metastasis at presentation ($P = 0.939$) [Table 2].

DISCUSSION

COX, officially known as PG-endoperoxide synthase, is an enzyme that is responsible for the formation of PGs from arachidonic acid. The PGs are autocoid mediators that affect virtually all known physiological and pathological processes via their reversible interaction with G-protein coupled membrane receptors. There are two isoforms of COX, namely, COX-1 and COX-2 which are almost identical in their structure, but for the substitution of isoleucine at position 523 in COX-1 with valine in COX-2.

Earlier studies showed that while both enzymes carry out essentially the same catalytic reaction and have similar primary protein structures, many of the inflammatory or inducible effects of COX appear to be mediated by COX-2, while many of the “housekeeping” effects of COX appear to be mediated by COX-1. Later studies revealed that the COX-1 and COX-2 proteins are derived from distinct genes. COX-2 gene can be induced by hormones, growth factors, phorbol esters, cyclic adenosine monophosphate, inflammatory factors and cytokines.

Enhanced synthesis of PGs, due to the upregulation of COX-2, increases the proliferative activity of neoplastic cells, cancer invasiveness and metastasis. Despite extensive studies, there is limited data available on COX-2 expression in HNSCC and its relation with different clinicopathological parameters in the Indian context. The COX-2 initiated signaling pathways can control cell proliferation and accumulating evidence shows that COX-2 is widely overexpressed in HNSCC.

Demographic profile
In our study, performed on 90 cases of HNSCCs, 51.1% of the patients were aged above 60 years. The mean age of the patients was 61.33 ± 10.38 years. The majority of the patients were males ($n = 72/90; 80\%$) and there were 18 (20%) females. The ratio of males to females was 4:1. A bias may be present in the study as it was conducted in an armed forces hospital where there is a male preponderance. The majority of the patients hailed from a rural background in this study (71.1%).

![Figure 1: H and E stain (x200). (a) Well differentiated squamous cell carcinoma. (b) Moderately differentiated squamous cell carcinoma. (c) Poorly differentiated squamous cell carcinoma](image-url)
As opined by various authors, head and neck cancer is known to occur primarily in older adults, with most patients being more than the age of 45 years. Although recent studies have demonstrated a steady rise in the incidence of HNSCCs in younger adults (18–45 years) due to human papillomavirus (HPV) related etiology, such a trend was not seen in our study. This possibly indicates that HNSCC in India has predominantly a non HPV related, tobacco and alcohol-associated etiology.

The disease shows a male preponderance in almost all countries, with rates two to four times higher among males than females. This was in concordance with our findings and may be suggestive of a lower incidence of tobacco and alcohol consumption by females in India.

As opposed to our results, most of the studies available in literature show a higher prevalence of HNSCCs in urban as compared to rural areas. The possible reason for this variation in our results might be because, in an Indian scenario, the practices of betel quid chewing, consumption of “khaini” or supari, smoking or alcohol consumption, which are well recognized risk factors for HNSCCs, are more common in the rural population.

In this study, most of the HNSCCs (57.8%) were well-differentiated histopathologically (n = 52), while 41.1% were moderately differentiated (n = 37). Only 1.1% (n = 1) of the cases was poorly differentiated. This is in keeping

| Characteristic                | Number of cases | Mean expression | SD    | Statistical significance, P |
|------------------------------|-----------------|-----------------|-------|-----------------------------|
| Grade                        |                 |                 |       |                             |
| Well differentiated           | 52              | 1.73            | 0.77  | 0.002                       |
| Moderately differentiated     | 37              | 2.30            | 0.78  |                             |
| Poorly differentiated         | 1               | 1.00            | 0.00  |                             |
| Tumor size/clinical stage (T) |                 |                 |       |                             |
| T1                           | 21              | 1.71            | 0.46  | 0.001                       |
| T2                           | 46              | 1.91            | 0.79  |                             |
| T3                           | 11              | 1.64            | 0.81  |                             |
| T4                           | 13              | 2.77            | 0.93  |                             |
| Nodal status (N)              |                 |                 |       |                             |
| N0                           | 67              | 1.84            | 0.665 | 0.024                       |
| N1                           | 15              | 2.47            | 0.83  |                             |
| N2                           | 8               | 2.00            | 1.51  |                             |
| Distant metastasis (M)        |                 |                 |       |                             |
| M0                           | 88              | 1.95            | 0.83  | 0.939                       |
| M1                           | 2               | 2.00            | 0.00  |                             |
| Tumor depth (maximum) (cm)    |                 |                 |       |                             |
| ≤0.5                         | 7               | 1.57            | 0.54  | 0.019                       |
| 0.5-1                        | 44              | 2.05            | 0.81  |                             |
| 1-1.5                        | 17              | 1.65            | 0.86  |                             |
| 1.5-2                        | 12              | 1.75            | 0.62  |                             |
| >2                           | 10              | 2.60            | 0.84  |                             |
| Lvi/Pni                      |                 |                 |       |                             |
| None                         | 71              | 1.85            | 0.71  | 0.005                       |
| Lymphovascular               | 17              | 2.24            | 1.03  |                             |
| Lympho + perineural          | 2               | 3.50            | 0.71  |                             |

Lvi: Lymphovascular invasion, Pni: Perineural invasion, SD: Standard deviation
with other studies mentioned in literature, wherein the most commonly found histological grade was well differentiated although extensive search in indexed journals did not yield any comment on the prevalence of carcinoma based on differentiation.\cite{6,8,11}

**Pattern of immunostaining**

The staining intensity and extent was mainly localized or was seen to be stronger in the peripheries of tumor islands. This observation is in accordance with other studies. The justification for such a pattern lies in the fact that the staining reaction varies with cellular differentiation and therefore reiterates the presence of these receptors in undifferentiated cells.\cite{6,19}

Immunoreactivity for COX-2 was patchy and also seen in stromal cells including macrophages and neutrophils. These findings might be suggestive of an interaction between the stromal cells and tumor cells thus affecting COX-2 expression.

**Prevalence of cyclooxygenase-2 expression**

Our observed prevalence of COX-2 protein positivity by immunohistochemistry was 97.8\% (n = 88). Negative expression was seen in 2.2\% (n = 2) cases. These results are in close proximation to those obtained by Goto et al.\cite{9} who demonstrated 97.3\% immunostaining in HNSCCs and Søland et al.\cite{21} who showed 98\% COX-2 staining in oral squamous cell carcinomas (OSCCs). Overexpression was observed in 76.7\% of the cases. These results are similar to those observed by other researchers.\cite{21}

**Correlation of histological grade/degree of differentiation with cyclooxygenase-2 expression**

In this study, positive expression was found to be higher in moderately differentiated tumors while negative expression was more commonly seen in well-differentiated tumors. This is in agreement with the results reported by other investigators.\cite{6,9}\footnote{This finding suggests that, with decreasing differentiation of tumor, COX-2 immunostaining intensity increases (P = 0.001; highly significant).}

Assuming that moderately and poorly differentiated tumors behave more aggressively, intensity of COX-2 expression may correlate well with the aggressiveness of disease. However, not all studies agree on this, and there lies some ambiguity in the matter. Shigeto Itoh et al.\cite{22} could not find any correlation of COX-2 status with the histological grade of tumors in HNSCCs.\cite{23}

**Correlation of tumor size and maximum tumor depth with cyclooxygenase-2 expression**

Significant correlation was found between COX-2 overexpression and tumor size in our study. T\textsubscript{3} and T\textsubscript{4} tumors were associated with a higher percentage of COX-2 overexpressed cases as compared to T\textsubscript{1} and T\textsubscript{2} tumors. These results are in concordance with earlier studies.\cite{24}

The mean expression of COX-2 was seen to increase significantly with increasing tumor depth (P = 0.019). These results are in concurrence with those obtained by Woś et al.\cite{25}

This finding is another indication of the high prognostic value of COX-2 in HNSCCs, as tumor depth is a well-identified prognostic indicator in HNSCCs.

In our study, nodal metastasis was present in only 23 cases. Out of these, COX-2 positivity was present in 22 cases, while negative expression was noted only in a single case. COX-2 overexpression was found in 18 cases. Significant association was found between nodal metastasis and COX-2 expression (P = 0.024). Other Indian studies have also given similar results.\cite{6}

**Correlation of lymphovascular/perineural invasion with cyclooxygenase-2 expression**

In our study, 78.9\% of the patients (n = 71) did not show either lvi/pni. A total of 17 patients (18.9\%) showed only lvi, while 2 (2.2\%) showed both lvi and pni. Perineural invasion alone was not seen in any of the cases in our study. We found a significant association between lvi/pni and COX-2 overexpression (P = 0.005). Though studies pertaining to the prognostic implication of lvi/pni in HNSCCs are present,\cite{24,25} there’s a paucity of literature studying the correlation between COX-2 and lvi/pni. Our study attempts to shed some light upon this unexplored area. These results might indicate that, the role of COX-2 in tumor metastasis is through lvi spread. Another possibility that exists is that tumors having overexpression of COX-2, which were also found to be of a higher grade, had an earlier involvement of vessels or nerves.

Only 2 (2.2\%) patients in this study had distant metastasis at the time of presentation. No significant association was found between COX-2 positivity and distant metastasis. This is in opposition to the scant research available in indexed literature, which attaches a significant association of COX-2 with metastasis.\cite{10}\footnote{The probable reason for such a discord in our study might be the lack of surgical intervention in cases of HNSCCs presenting with distant metastasis to our institution. As our study includes only resected specimens of HNSCCs, these results can thus be explained.}

**CONCLUSIONS**

This study supports the view that COX-2 expression is related to tumor growth, differentiation and aggressiveness.
and there is a possible scope of using this for targeted therapy in HNSCCs. It also identifies COX-2 as a good independent prognostic marker in HNSCCs in the Indian context.

Acknowledgement
The authors would like to thank the technical staff of the laboratory department for their skillful assistance.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. More Y, D'Cruz AK. Oral cancer: Review of current management strategies. Natl Med J India 2013;26:152-8.
2. Saba NF, Choi M, Muller S, Hyung Ju C, Tighiouart M, Shin DM. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase signaling pathways: Preclinical and clinical studies. Clin Cancer Res 2013;19:1244-56.
3. Day GL, Blot WJ. Second primary tumors in patients with oral cancer. Br J Cancer 1992;70:14-9.
4. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bel-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
5. Tsuji M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
6. Mohammad S, Ram H, Gupta PN, Husain N, Bhatt ML. Overexpression of COX-2 in oral squamous cell carcinoma patients undergoing chemoradiotherapy. Natl J Maxillofac Surg 2011;2:17-21.
7. Itoh S, Matsui K, Furuta I, Takano Y. Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: Its importance as a prognostic predictor. Oral Oncol 2003;39:293-35.
8. Yeole BB. Trends in incidence of head and neck cancers in India. Asian Pac J Cancer Prev 2007;8:607-12.
9. Goto R, Hoshikawa H, Fujii T, Indo K, Yoshino K, Imaida K, et al. Clinicopathological significance of cyclooxygenase-2 expression analysis in hypopharyngeal squamous cell carcinoma. Oncol Rep 2008;19:645-50.
10. Cao J, Guo T, Dong Q, Zhang J, Li Y. miR-26b is downregulated in human tongue squamous cell carcinoma and regulates cell proliferation and metastasis through a COX-2-dependent mechanism. Oncol Rep 2015;33:974-80.
11. Abrahao AC, Castilho RM, Suardize CH, Molinolo AA, dos Santos-Pinto D Jr, Gutkind JS. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol 2010;46:880-7.
12. Kumar V, Cotran RS, Robbins SL. Neoplasia. In: Kumar V, Abbas AK, Aster JC, editors. Robbins and Cotran Pathologic Basis of Disease South Asia Edition. Vol. 1, 9th ed. New Delhi: Reed Elsevier India Pvt Ltd; 2014. p. 265-340.
13. Reed DW, Bradshaw WS, Xie W, Simmons DL. In vivo and in vitro expression of a non-mammalian cyclooxygenase-1. Prostaglandins 1996;52:269-84.
14. Tsuji M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
15. Kelley DJ, Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, et al. Benzoylpyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 1997;18:795-9.
16. Shenoi R, Devruikhlar V, Chaudhuri, Sharma BK, Sapre SB, Chikhale A. Demographic and clinical profile of oral squamous cell carcinoma patients: A retrospective study. Indian J Cancer 2012;49:21-6.
17. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9.
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
19. Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol 2010;2:13.
20. Soland TM, Husvik C, Koppang HS, Boysen I, Clausen OP, et al. A study of phosphorylated ERK1/2 and COX-2 in early stage (T1-T2) oral squamous cell carcinomas. J Oral Pathol Med 2008;37:535-42.
21. Chan G, OByle J. Cyclooxygenase-2 expression is upregulated in Squamous Cell Carcinoma of the Head and Neck. Cancer Res 1999;59:991-4.
22. Sakurai K, Urade M, Noguchi S, Hashiuchi S, Takaoka K, Segawa E, et al. Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIalpha expression in oral carcinoma. Head Neck 2007;29:1002-9.
23. Woo S, Brys M, Lewy-Trenda I, Stasikowska O, Papiez P, Papierz W, et al. Analysis of HIF-1α and COX-2 expression in tumor stroma and correlation with the degree of neoplasm invasiveness in laryngeal cancer-preliminary study. Otolaryngol Pol 2011;65:102-8.
24. Brannigan BW, Cigudosa JC, Jiang P, Lemmon MA, Maris JM, Brannigan BH. Analysis of the PI3K pathway in oral squamous cell carcinoma. Cancer Res 2013;73:612-20.
25. Yeh CF, Li WY, Yang MH, Chu PY, Lu YT, Wang YF, et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral squamous cell carcinoma cell line. Oral Oncol 2015;50:857-62.